Skip to content

Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes

Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes: A Randomized Controlled Trial of SHIFT2

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05639088
Acronym
SHIFT2
Enrollment
109
Registered
2022-12-06
Start date
2023-08-24
Completion date
2026-12-11
Last updated
2026-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Diabetes Management, Transition

Brief summary

The purpose of this research study is to evaluate a transition preparation program designed for adolescents and young adults (AYAs) with type 1 diabetes (T1D). This transition program will support AYAs as they prepare to transition from pediatric to adult endocrinology medical care and will also include a caregiver. Results from this study will inform clinical recommendations regarding self-management best practices for AYAs with T1D prior to transitioning to adult medical care.

Detailed description

Investigators will recruit adolescents and young adults ages 16-22 years with T1D and a parent/guardian. Families will participate in one of two 6-month treatments: 1) SHIFT2, engaging in monthly sessions with transition coaches providing education on diabetes management and healthcare transition, or 2) Enhanced treatment (TAU+), engaging in routine medical care and receiving monthly education (no coaches).

Interventions

OTHEREducational materials

AYA and caregivers will receive educational materials regarding healthcare transition and diabetes management monthly for 6 months

BEHAVIORALTransition preparation program

AYA will participate in virtual or in-person sessions with a transition coach and receive bi-weekly messages that encourage self-management. Caregivers will attend a virtual or in-person session with a transition coach.

Sponsors

Virginia Commonwealth University
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

AYA: 1. Type 1 Diabetes diagnosis for at least 1 year (as documented in medical record) 2. 16-22 years old 3. English speaking 4. Children's Hospital of Richmond patient (Division of Pediatric Endocrinology) 5. must have a caregiver willing to participate Caregiver: 1. Age greater than 18 years 2. Provides care to AYA and willing to participate

Exclusion criteria

AYA: 1. Non-English speaking 2. Significant psychiatric, cognitive, medical or developmental conditions that would impair their ability to complete assessments and/or engage in diabetes self-care behaviors (e.g., malignancies, psychosis, intellectual disability 3. Hospitalization for depression, suicidal ideation or other psychiatric disorder within the past 12 months. Life time history of psychotic disorder 4. Medically-induced diabetes or diagnosis of diabetes other than type 1 diabetes. 5. Currently pregnant, pregnant within the past 6 months, currently breastfeeding or planning to become pregnant within the next 12 months. 6. Another member of the household (other than the participating parent) is a participant or staff member on this study. 7. Participation in another research study that may interfere with this study. 8. Previous participation in the SHIFT pilot study Caregiver: 1. Non-English speaking 2. Significant psychiatric, cognitive, developmental conditions that would impair their ability to complete assessments and/or engage in supporting the AYA with diabetes self-care behaviors (e.g., psychosis, intellectual disability) 3. Another member of the home (not AYA) is a participant/staff member on current study 4. Participation in another research study that may interfere with current study 5. Previous participation in SHIFT pilot study

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin A1C (HbA1C)6 monthsHbA1C will be assessed using a standard assay from a routine blood draw or an at-home testing kit
Change in transition readinessBaseline to 6 monthsTransition readiness will be measured using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) scale, which will be completed by AYAs.
Change in diabetes adherenceBaseline to 6 monthsDiabetes adherence will be assessed using the Self-Care Inventory-Revised, which will be completed by both AYA and caregivers.
Attendance at clinic visits6 monthsAttendance at routine clinic visits will be determined from medical records and will be assessed by the number of regularly scheduled visits attended.

Secondary

MeasureTime frameDescription
HbA1C12 monthsHbA1C will be assessed using a standard assay from a routine blood draw or an at-home testing kit.
Diabetes-related events12 monthsNumber of diabetes-related events will be determined from medical records
Change in transition readinessBaseline to 12 monthsTransition readiness will be measured using the Readiness Assessment of Emerging Adults with Type 1 Diabetes Diagnosed in Youth (READDY) scale, which will be completed by AYAs.
Change in diabetes adherenceBaseline to 12 monthsDiabetes adherence will be assessed using the Self-Care Inventory-Revised, which will be completed by both AYA and caregivers.
Attendance at clinic visits12 monthsAttendance at routine clinic visits will be determined from medical records.
Change in diabetes supportBaseline to 12 monthsDiabetes support will be assessed using the Diabetes Social Support Questionnaire - Family Version (DDSQ-Family), which will be completed by AYAs.
Change in Diabetes DistressBaseline to 12 monthsDiabetes distress will be assessed using the Diabetes Distress Scale (DDS) for Type 1 Diabetes (DDS), which will be completed by both AYA and caregivers. AYA will complete specific versions corresponding to age (\>18 or \<18) and caregivers complete their own version of the measure.
Change in Self EfficacyBaseline to 12 monthsSelf-efficacy will be measured using the Self-efficacy for Diabetes Self-Management scale (SEDSM), which will be completed by AYAs.
Change in Quality of LifeBaseline to 12 monthsQuality of life will be measured using the T1D and Life (T1DAL), which will be completed by AYA and caregiver.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLaura Caccavale

Virginia Commonwealth University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 8, 2026